Praveen Bathini

Dr. Praveen Bathini

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Ageing Research Reviews
Verified
Journal Article
Closed access
PBPraveen Bathini
Praveen Bathini
EBEmanuele Brai
Emanuele Brai
LALavinia Alberi Auber
Lavinia Alberi Auber

20 February 2020 in Current Opinion in Neurology
Verified
Journal Article
Closed access
MSMahtab Sadrameli
Mahtab Sadrameli
PBPraveen Bathini
Praveen Bathini
LALavinia Alberi
Lavinia Alberi
Purpose of review: The review article discusses the association between periodontal disease and the development of dementia. Recent findings: In the last decade, increasing evidence has pointed to a microbial and inflammatory origin for Alzheimer's disease with the discovery of oral and airway bacteria, viruses, and fungal species in the brain of patients with Alzheimer's disease. Furthermore, recognized as the culprit of neural network dysfunction, β-amyloid oligomeric species have antimicrobial properties reinforcing the idea that dysbiosis in the host–microbiota interaction can be at the origin of dementia. Periodontitis (gum disease), a persistent low-grade inflammatory condition, caused by pathogenic microorganisms, has been linked to an increased β-amyloid burden and cognitive disabilities later in life. Summary: The pathogens of periodontal disease and the subsequent chronic inflammatory responses have significant implications on the development of Alzheimer's disease. The exact molecular mechanism by which Porphyromonas gingivalis and periodontal disease are involved in the pathogenicity of Alzheimer's disease is not currently evident. Understanding this causality can be instrumental in the development of treatments for this yet uncurable disease.

1 January 2018 in Journal of Experimental Neuroscience
Verified
Journal Article
Open access
SMSwananda V Marathe
Swananda V Marathe
PDPriyal L D’almeida
Priyal L D’almeida
GVGarima Virmani
Garima Virmani
PBPraveen Bathini
Praveen Bathini
LALavinia Alberi
Lavinia Alberi
Major depressive disorder (MDD) is one of the most common neuropsychiatric disorders affecting over one-fifth of the population worldwide. Owing to our limited understanding of the pathophysiology of MDD, the quest for finding novel antidepressant drug targets is severely impeded. Monoamine hypothesis of MDD provides a robust theoretical framework, forming the core of a large jigsaw puzzle, around which we must look for the vital missing pieces. Growing evidence suggests that the glial loss observed in key regions of the limbic system in depressed patients, at least partly, accounts for the structural and cognitive manifestations of MDD. Studies in animal models have subsequently hinted at the possibility that the glial atrophy may play a causative role in the precipitation of depressive symptoms. Antidepressants as well as monoamine neurotransmitters exert profound effects on the gene expression and metabolism in astrocytes. This raises an intriguing possibility that the astrocytes may play a central role alongside neurons in the behavioral effects of antidepressant drugs. In this article, we discuss the gene expression and metabolic changes brought about by antidepressants in astrocytes, which could be of relevance to synaptic plasticity and behavioral effects of antidepressant treatments.

1 April 2019 in Neurobiology of Aging
Verified
Journal Article
Closed access
PBPraveen Bathini
Praveen Bathini
AMAntoine Mottas
Antoine Mottas
MJMuriel Jaquet
Muriel Jaquet
EBEmanuele Brai
Emanuele Brai
LALavinia Alberi
Lavinia Alberi

1 January 2020 in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Verified
Journal Article
Closed access
PDF file
PBPraveen Bathini
Praveen Bathini
SFSandrine Foucras
Sandrine Foucras
IDIsabelle Dupanloup
Isabelle Dupanloup
HIHira Imeri
Hira Imeri
APAmalia Perna
Amalia Perna
LALavinia Auber Alberi
Lavinia Auber Alberi

6 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
PBPraveen Bathini
Praveen Bathini
TSTao Sun
Tao Sun
MSMathias Schenk
Mathias Schenk
Stephan SchillingStephan Schilling
Stephan Schilling
NMNathan J McDannold
Nathan J McDannold
CLCynthia A Lemere
Cynthia A Lemere
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and hyperphosphorylated tau in the brain. Currently, therapeutic agents targeting amyloid appear promising for AD, however, delivery to the CNS is limited due to the blood-brain-barrier (BBB). Focused ultrasound (FUS) is a method to induce a temporary opening of the BBB to enhance the delivery of therapeutic agents to the CNS. In this study, we evaluated the acute effects of FUS and whether the use of FUS-induced BBB opening enhances the delivery of 07/2a mAb, an anti-pyroglutamate-3 Aβ antibody, in aged 24 mo-old APP/PS1dE9 transgenic mice. FUS was performed either unilaterally or bilaterally with mAb infusion and the short-term effect was analyzed 4 h and 72 h post-treatment. Quantitative analysis by ELISA showed a 5–6-fold increase in 07/2a mAb levels in the brain at both time points and an increased brain-to-blood ratio of the antibody. Immunohistochemistry demonstrated an increase in IgG2a mAb detection particularly in the cortex, enhanced immunoreactivity of resident Iba1+ and phagocytic CD68+ microglial cells, and a transient increase in the infiltration of Ly6G+ immune cells. Cerebral microbleeds were not altered in the unilaterally or bilaterally sonicated hemispheres. Overall, this study shows the potential of FUS therapy for the enhanced delivery of CNS therapeutics.